SCIENCE IN THE NEWS DAILY
Promising Alzheimer's Drug Approved for Late-Stage Trials
from USA Today
An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.
Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.
In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.
Read more ...
Connect With Us:
PODCAST & VIDEO: 3D Printing Replacement Body Parts
Regenerative medicine, a fledgling field with the aim of regrowing parts from a person’s own cells, is being amplified with 3D-printing technology, which can now use organic materials to create scaffolds that cells need to grow into their final forms. Richard Wysk, a professor of industrial and systems engineering at North Carolina State University, discusses the latest successes with this research, and the timeline for creating more complicated structures.
To view all multimedia content, click "Latest Multimedia."
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.